What is Pherecydes Pharma?
Pherecydes Pharma operates at the intersection of advanced medical research and enterprise-scale pharmaceutical development. The company is dedicated to pioneering innovative therapeutic solutions, focusing on high-growth potential areas within the life sciences industry. By maintaining a rigorous approach to clinical validation and strategic partnerships, Pherecydes Pharma has established itself as a key player capable of addressing critical unmet medical needs. Its market position is bolstered by a commitment to deeptech innovation and a scalable business model that attracts top-tier venture capital interest.
How much funding has Pherecydes Pharma raised?
Pherecydes Pharma has raised a total of $15.5M across 3 funding rounds:
Series A
$2.3M
Unspecified
$2.9M
Series B
$10.3M
Series A (2014): $2.3M with participation from Auriga Partners
Unspecified (2015): $2.9M, investors not publicly disclosed
Series B (2018): $10.3M supported by Fa-Dièse, Omnes Capital, Auriga Partners, and Go Capital
Key Investors in Pherecydes Pharma
Fa-Dièse
A Paris-based micro VC fund that combines the philosophy of business angels with venture capital demands, focusing on early-stage startups in digital, hardware, and life sciences.
Omnes Capital
A leading European private equity firm managing over 6.7 billion euros, specializing in energy transition, sustainable cities, and deeptech innovation.
Go Capital
A strategic investment firm focused on bridging advanced technology between international markets, particularly in life sciences, cyber security, and artificial intelligence.
What's next for Pherecydes Pharma?
With the recent infusion of capital, Pherecydes Pharma is poised to scale its operational capabilities and expand its clinical pipeline. The strategic focus will likely shift toward optimizing manufacturing processes and accelerating market penetration for its lead candidates. As the company moves beyond its Series B milestone, the emphasis will remain on achieving key regulatory milestones and fostering collaborative relationships with global strategic partners. This phase of development is critical for transforming early-stage research into commercially viable enterprise solutions, ensuring the company remains at the forefront of biotech innovation.
See full Pherecydes Pharma company page
